Início › Leucemia › Illinois › Chicago
Ensaios clínicos de Leucemia em Chicago, IL
16 estudos para Leucemia estão buscando participantes em locais em Chicago e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecrutandoFase 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecrutandoFase 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecrutandoFase 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecrutandoFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RecrutandoFase 1/2
- Research Site, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecrutandoFase 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Recrutando
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
RecrutandoFase 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecrutandoEstudo observacional
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecrutandoFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecrutandoFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
Recrutando
- UChicago Medicine Comprehensive Cancer Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
RecrutandoFase 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Recrutando
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecrutandoFase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Ensaios de Leucemia em outras cidades
- Houston, TX28 estudos
- Boston, MA25 estudos
- New York City, NY19 estudos
- Los Angeles, CA16 estudos
- Durham, NC13 estudos
- Nashville, TN12 estudos
- Columbus, OH12 estudos
- Baldwin Park, CA12 estudos
- Philadelphia, PA12 estudos
- Seattle, WA11 estudos
- Milwaukee, WI11 estudos
- Birmingham, AL10 estudos
Outros estudos em Chicago
- Câncer de Pulmão de Não Pequenas Células61 estudos
- Câncer de Mama58 estudos
- Câncer (todos os tipos)52 estudos
- Câncer Metastático45 estudos
- Câncer de Próstata45 estudos
- Obesidade42 estudos
- Câncer de Pulmão41 estudos
- Câncer de Ovário36 estudos
- Acidente Vascular Cerebral34 estudos
- Insuficiência Cardíaca32 estudos
- Câncer Colorretal32 estudos
- Sobrepeso28 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.